Inventor · disambiguated record
Aaron Osborne
Also filed as: OSBORNE AARON · OSBORNE AARON R
2 granted patents·10 pending applications·14 citations·filing 2004–2023
55Inventor score
Files withHOFFMANN LA ROCHE3OSBORNE AARON2UNIV SOUTH FLORIDA2ADVERUM BIOTECHNOLOGIES INC1BYK CHEMIE GMBH1
Top patents by PatentIndex Score
12 records- 0166US9089375B2Combined intramedullary and extramedullary surgical aiming system and methodSMITH JOEL·Filed 2014·Granted Jul 28, 2015·12 cites·9 claims
- 0263US7601696B1Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatmentUNIV SOUTH FLORIDA·Filed 2004·Granted Oct 13, 2009·2 cites·7 claims
- 0362US2023416353A1Treatment of ophthalmologic diseasesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0456US2022162296A1Personalized treatment of ophthalmologic diseasesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 0553US2022289896A1Additive for temperature adaptive rheology profileBYK CHEMIE GMBH·Filed 2020·Application pending·0 cites
- 0651US2021139576A1Treatment of ophthalmologic diseasesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 0744US2021100856A1Methods of treating ocular neovascular diseases using aav2 variants encoding afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 0842US2016129080A1Treatment of polypoidal chroidal vasculopathyOSBORNE AARON·Filed 2014·Application pending·0 cites
- 0941US2022067460A1Variance Characterization Based on Feature ContributionCAPITAL ONE SERVICES LLC·Filed 2020·Application pending·0 cites
- 1040US2007184481A1Assay For Transcriptionally Active Methylated PromotersUNIV SOUTH FLORIDA·Filed 2007·Application pending·0 cites
- 1131US2015297675A1Use of a vegf antagonist in treating ocular vascular proliferative diseasesOSBORNE AARON·Filed 2013·Application pending·0 cites
- 1225US2016374738A1Combined Intramedullary and Extramedullary Surgical Aiming System And MethodINTERFIX LLC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →